Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/nejm197507102930215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel intervention for alcohol-associated liver disease.
World J Gastroenterol
October 2024
Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, The Affiliated Lihuili Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China.
A recently published article in the clarified that elafibranor, a dual peroxisome proliferator activated receptor α/δ (PPARα/δ) agonist, reduced inflammation and fibrosis in alcohol-associated liver disease (ALD). This letter aims to discuss the findings presented in that article. ALD is a global health problem, and no effective drugs has been approved by the Food and Drug Administration to cure it.
View Article and Find Full Text PDFDual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?
World J Gastroenterol
October 2024
Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
In this letter, we review the article "Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease". We focus specifically on the detrimental effects of alcohol-associated liver disease (ALD) on human health. Given its insidious onset and increasing incidence, increasing awareness of ALD can contribute to reducing the prevalence of liver diseases.
View Article and Find Full Text PDFPhase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
N Engl J Med
May 2024
Newcastle University, Newcastle Upon Tyne, United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!